Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
S0026
Closed
Phase
Accrual
13%
Closed
Phase
Accrual
46%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0027
Closed
Phase
Accrual
16%
SWOG Clinical Trial Number
S0020
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
34%
SWOG Clinical Trial Number
S0029
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0000

Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
07-25-2001
Closed
06-24-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0107

A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
07-01-2001
Closed
06-01-2003
Closed
Phase
Accrual
81%
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0111
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0102

Docetaxel and Vinorelbine Plus Filgrastim for HER-2 Negative, Stage IV Breast Cancer, Phase II

Research Committee(s)
Breast Cancer
Activated
05-01-2001
Closed
01-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0109

A Phase II Study of Flavopiridol (NSC-649890) 1 Hour Bolus Days 1-3 Q 21 Days in Patients with Advanced Renal Cell Cancer

Research Committee(s)
Genitourinary Cancer
Activated
05-01-2001
Closed
02-01-2002
Closed
Phase
Accrual
87%
Published
SWOG Clinical Trial Number
S0108

Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma

Research Committee(s)
Lymphoma
Activated
04-15-2001
Closed
12-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0101

A Phase II Study of Gemcitabine Plus Irinotecan (CPT-11) In Patients With Esophageal Cancer.

Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2001
Closed
02-01-2003
Closed
Phase
Accrual
33%
SWOG Clinical Trial Number
S0022
Closed
Phase
Accrual
100%
Published